Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve

[Image: see text] The phosphoinositide kinase PIKfyve has emerged as a new potential therapeutic target in various cancers. However, limited clinical progress has been achieved with PIKfyve inhibitors. Here, we report the discovery of a first-in-class PIKfyve degrader 12d (PIK5-12d) by employing the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chungen, Qiao, Yuanyuan, Jiang, Xia, Liu, Lianchao, Zheng, Yang, Qiu, Yudi, Cheng, Caleb, Zhou, Fengtao, Zhou, Yang, Huang, Weixue, Ren, Xiaomei, Wang, Yuzhuo, Wang, Zhen, Chinnaiyan, Arul M., Ding, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510382/
https://www.ncbi.nlm.nih.gov/pubmed/37605297
http://dx.doi.org/10.1021/acs.jmedchem.3c00912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510382/
https://www.ncbi.nlm.nih.gov/pubmed/37605297
http://dx.doi.org/10.1021/acs.jmedchem.3c00912

Ejemplares similares